153 related articles for article (PubMed ID: 15069120)
1. Re: Playing the old piano: another tune for endocrine therapy.
Koeberle D; Perey L; Thuerlimann B;
J Natl Cancer Inst; 2004 Apr; 96(7):555-6; author reply 556-7. PubMed ID: 15069120
[No Abstract] [Full Text] [Related]
2. Playing the old piano: another tune for endocrine therapy?
Hayes DF
J Natl Cancer Inst; 2003 Nov; 95(21):1565-7. PubMed ID: 14600082
[No Abstract] [Full Text] [Related]
3. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
4. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
Terakawa N
Oncology; 2000; 59 Suppl 1():3-4. PubMed ID: 11096349
[No Abstract] [Full Text] [Related]
5. How is tamoxifen's action subverted?
Jordan VC
J Natl Cancer Inst; 2000 Jan; 92(2):92-4. PubMed ID: 10639501
[No Abstract] [Full Text] [Related]
6. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
7. Current status of selective estrogen receptor modulators (SERMs).
Conzen SD
Cancer J; 2003; 9(1):4-14. PubMed ID: 12602762
[No Abstract] [Full Text] [Related]
8. Fulvestrant.
Cheung KL; Robertson JF
Expert Opin Investig Drugs; 2002 Feb; 11(2):303-8. PubMed ID: 11829719
[TBL] [Abstract][Full Text] [Related]
9. [Hormone therapy and breast cancer].
de Cremoux P
Bull Cancer; 2011 Nov; 98(11):1311-9. PubMed ID: 22020743
[TBL] [Abstract][Full Text] [Related]
10. A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer.
Bogush EA; Ravcheeva AB; Bogush TA; Zabotina TN; Kadagidze ZG; Davydov MI
Dokl Biochem Biophys; 2007; 413():83-7. PubMed ID: 17546960
[No Abstract] [Full Text] [Related]
11. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
Planas-Silva MD; Waltz PK; Kilker RL
J Steroid Biochem Mol Biol; 2006 Mar; 98(4-5):193-8. PubMed ID: 16464573
[TBL] [Abstract][Full Text] [Related]
12. The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.
Frassoldati A; Guarneri V; Conte P
Cancer Biol Ther; 2009 Aug; 8(15):1456-8. PubMed ID: 19617703
[No Abstract] [Full Text] [Related]
13. In search of the perfect SERM: beyond tamoxifen and raloxifene.
McNeil C
J Natl Cancer Inst; 1998 Jul; 90(13):956-7. PubMed ID: 9665139
[No Abstract] [Full Text] [Related]
14. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
15. Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
Journé F; Body JJ; Leclercq G; Laurent G
Expert Opin Drug Saf; 2008 May; 7(3):241-58. PubMed ID: 18462183
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma.
Lamb CA; Helguero LA; Fabris V; Lucas C; Molinolo AA; Lanari C
Breast Cancer Res Treat; 2003 May; 79(1):25-35. PubMed ID: 12779079
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
18. Caring for the breast cancer survivor.
Abdel-Razeq H
Am J Med; 2011 Feb; 124(2):e11; author reply e13. PubMed ID: 21295181
[No Abstract] [Full Text] [Related]
19. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
Buzdar AU; Robertson JF
Ann Pharmacother; 2006 Sep; 40(9):1572-83. PubMed ID: 16912252
[TBL] [Abstract][Full Text] [Related]
20. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
